India Pharma Outlook Team | Thursday, 13 August 2026
Gujarat is drawing fresh pharma investment worth INR 2,500-3,000 crore. The money is going into new drug manufacturing facilities across the state.
The investment follows approvals for 59 new allopathic medicine plants during FY2025-26. The latest pharma investment push could further strengthen Gujarat’s position as a major drug manufacturing hub.
Several upcoming facilities are being designed with export-ready infrastructure. These plants are expected to serve both Indian and global markets.
Gujarat's Food and Drugs Control Administration (FDCA) approved 330 fresh licenses during FY2025-26. These included approvals for new manufacturing units and loan licensing arrangements. Of the total licenses, 59 were for new plants. Another 271 were issued under the loan licensing system.
FDCA officials said the new plants are expected to begin operations soon. Their addition will increase manufacturing capacity across the state's pharma sector. The estimated investment is based on the rising cost of modern drug manufacturing facilities. New-age plants typically require INR 40-50 crore each. Some companies are investing considerably more.
Based on these estimates, the total fresh investment in the 59 plants could reach INR 2,500-3,000 crore.
Also Read: India's Path to Billion-Dollar Drugs: Building a Strong Ecosystem
Gujarat's latest approvals build on several years of steady expansion. The state has approved more than 1,000 new allopathy medicine licenses since March 2019. The FDCA said this growth could strengthen Gujarat's position as a global pharmaceutical manufacturing base.
The state also recorded strong activity during FY2024-25. It approved 69 new own-plant licenses and 271 loan licenses during that period. Industry representatives say Gujarat's existing ecosystem is helping attract more companies. The state has a large base of pharmaceutical manufacturers and skilled workers.
Viranchi Shah, national spokesperson for the Indian Drug Manufacturers' Association, pointed to strong post-pandemic investment. He said several multinational companies have also established operations in Gujarat. Many of the new facilities are being built to meet international manufacturing standards. This could help companies target regulated overseas markets.
The new plants are expected to deliver more than additional production capacity. They could also improve compliance-focused manufacturing and support higher-value pharmaceutical exports.
The latest investment also shows that Gujarat continues to attract capital even after the post-pandemic investment surge. With new plants moving toward operations, the state could further expand its role in India's pharmaceutical supply chain.
